Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study

Ann Rheum Dis. 2020 Jul;79(7):986-988. doi: 10.1136/annrheumdis-2020-217903. Epub 2020 May 28.
No abstract available

Keywords: autoimmune diseases; biological therapy; epidemiology.

Publication types

  • Letter

MeSH terms

  • Abatacept / therapeutic use
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Azetidines / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / physiopathology
  • Disease Susceptibility
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Italy / epidemiology
  • Janus Kinase Inhibitors / therapeutic use
  • Logistic Models
  • Male
  • Middle Aged
  • Pandemics
  • Piperidines / therapeutic use
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / physiopathology
  • Proportional Hazards Models
  • Purines
  • Pyrazoles
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Rheumatic Diseases / drug therapy*
  • Risk Factors
  • SARS-CoV-2
  • Severity of Illness Index
  • Sulfonamides / therapeutic use
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Ustekinumab / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Azetidines
  • Interleukin 1 Receptor Antagonist Protein
  • Janus Kinase Inhibitors
  • Piperidines
  • Purines
  • Pyrazoles
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • Tumor Necrosis Factor Inhibitors
  • guselkumab
  • canakinumab
  • brodalumab
  • Abatacept
  • tofacitinib
  • ixekizumab
  • secukinumab
  • Ustekinumab
  • tocilizumab
  • baricitinib
  • sarilumab